Head to Head Comparison: Gain Therapeutics (NASDAQ:GANX) & BetterLife Pharma (OTCMKTS:BETRF)

Gain Therapeutics (NASDAQ:GANX) and BetterLife Pharma (OTCMKTS:BETRF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings and Valuation

This table compares Gain Therapeutics and BetterLife Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50,000.00	1,520.64	-$20.16 million	($0.61)	-2.95
BetterLife Pharma	N/A	N/A	-$2.55 million	N/A	N/A

BetterLife Pharma has lower revenue, but higher earnings than Gain Therapeutics.

Insider & Institutional Ownership

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of BetterLife Pharma shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 34.8% of BetterLife Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Gain Therapeutics and BetterLife Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1	0	4	0	2.60
BetterLife Pharma	0	0	0	0	0.00

Gain Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 372.22%. Given Gain Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Gain Therapeutics is more favorable than BetterLife Pharma.

Profitability

This table compares Gain Therapeutics and BetterLife Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-237.54%	-145.96%
BetterLife Pharma	N/A	N/A	-764.44%

Volatility & Risk

Gain Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, BetterLife Pharma has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.

Summary

Gain Therapeutics beats BetterLife Pharma on 6 of the 10 factors compared between the two stocks.

About Gain Therapeutics

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.